Last reviewed · How we verify
HM15211
HM15211 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T cell responses.
HM15211 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T cell responses. Used for Advanced solid tumors (Phase 2 development).
At a glance
| Generic name | HM15211 |
|---|---|
| Also known as | efocipegtrutide |
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Drug class | Bispecific antibody |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
HM15211 functions as a bispecific antibody designed to target multiple immune regulatory pathways simultaneously, thereby overcoming tumor immune evasion mechanisms. By engaging dual checkpoints, the drug aims to provide enhanced T cell activation and proliferation compared to single-checkpoint inhibitors. This approach is intended to improve anti-tumor immunity in patients with advanced malignancies.
Approved indications
- Advanced solid tumors (Phase 2 development)
Common side effects
Key clinical trials
- Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects (PHASE2)
- A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide) (PHASE1)
- A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |